glp 1 based drugs MCT2D This gentle GLP-1 Drugs from the Gray

In addition, it was observed that those who took less than 80% of their prescribed statin therapy versus patients who completed their therapy had a 45% increase in all-cause mortality and a 15% increase in CVD events, suggesting that completion of therapy is crucial [79]

doi: 10.1038/ijo.2015.172 17 DeaconCFHolstJJ

PMID 27059958

Landmark cases such as Bayer v

The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required

Conclusion Emerging evidence underscores the cardioprotective effects of GLP-1RAs, which make them potentially useful for different subpopulations of patients with cardiovascular diseases, including those with HFpEF